A total of more than 3 billion US dollars: Roche enters allogeneic T cell therapy

On September 7, Roche’s subsidiary Genentech and Adaptimmune reached a cooperation to jointly develop allogeneic T cell therapies to treat multiple tumor indications, with a total transaction amount of up to 3 billion US dollars

Adaptimmune stock price trend

From: Yahoo Finance

This partnership covers for up to five undisclosed cancer target share "stock type" (Off-the-shelf) cell therapy research and development and the new allogeneic personalized cell therapy platform development

After the transaction is concluded, Adaptimmune will receive an upfront payment of US$150 million and an additional US$150 million in payments over the next five years, as well as development, regulatory and commercial milestone payments and mid-single to low double-digit net sales The total price of tiered royalties may exceed 3 billion US dollars ; in addition, Adaptimmune has the option of 50/50 US profits/components of "off-the-shelf" products.

Not only Roche, this company has also reached cooperation with many large pharmaceutical companies

Adaptimmune's clinical stage pipeline

Adaptimmune's early clinical pipeline

The above pictures are from: Adaptimmune official website

Compared with CAR-T therapy, TCR-T has taken the lead in achieving breakthroughs in solid tumors

PR draft docking : WeChat insightxb

Contribution : WeChat insightxb; Email insight@dxy.